Objectives: The body adiposity index (BAI) is a proposed alternative to the body mass index (BMI) that has shown good cross‐sectional agreement with percent body fat (%BF) in validation studies. The objective of this study was to examine the ability of BAI to track adiposity change over time in a biracial sample of midlife women. Methods: African‐American (n = 159) and Caucasian (n = 206) women, aged 42–60 years, at the Chicago site of the Study of Women's Health Across the Nation were followed from 2002 to 2008. BAI and BMI were calculated from measurements taken at annual assessments. %BF was quantified using whole‐body dual‐energy X‐ray absorptiometry. Difference scores (BAIΔ, BMIΔ, and %BFΔ) quantified adiposity change over a mean of 1.6 (SD = 0.7) years. Lin's concordance correlation (ρc) and Bland–Altman limits‐of‐agreement assessed agreement between BAI and %BF. Results: In examining adiposity change, BAIΔ showed poor agreement with %BFΔ in the overall sample (ρc = 0.41), African‐American women (ρc = 0.36), and Caucasian women (ρc = 0.43). BAIΔ estimated %BFΔ with minimal bias (+0.4%) but low precision (±6.3%BF limits‐of‐agreement). %BFΔ had weaker correlations with BAIΔ (rs = 0.38–0.48) than with BMIΔ (rs = 0.48–0.59). BAI and BMI showed similar cross‐sectional associations with %BF in the overall sample and within each race (rs > 0.74). Conclusions: We conclude that BAI is less accurate than BMI in tracking adiposity change in midlife women, and would not be a suitable replacement for BMI in most research applications involving adiposity change. Am. J. Hum. Biol., 2012. © 2012 Wiley Periodicals, Inc.

Activated leukocyte cell adhesion molecule (ALCAM) is involved in cell-cell interactions in cancer. Shedding of its ectodomain by the metalloprotease ADAM17/TACE generates a soluble form (sALCAM). Here, we show that serum sALCAM levels were significantly higher in epithelial ovarian cancer (EOC) (p < 0.005) than in controls. The performance of sALCAM as classifier, tested by receiver operating characteristic curve, resulted in an area under the curve (AUC) of 0.8067. Serum sALCAM levels showed direct correlation with Carbohydrate Antigen-125 (CA125/MUC16). Moreover, significantly higher levels were found in type II tumors, even in stage I/II, suggesting that elevated sALCAM is an early feature of aggressive EOC. In addition, sALCAM levels were higher in ascites than in sera, suggesting local processing of ALCAM in the peritoneal cavity. In immunodeficient mice, intraperitoneally implanted with a human EOC cell line, human sALCAM progressively increased in serum and was even higher in the ascites. The biochemical characterization of the sALCAM in EOC sera and ascites, showed two predominant forms of approximately 95 and 65 kDa but no EOC-specific isoform. In addition, full-length transmembrane ALCAM but no soluble form was detected in tumor-derived exosomes found in ascites. Finally, in vitro invasion assays showed that inhibition of ADAM17/TACE activity decreased EOC invasive properties, while opposite effects were mediated by a sALCAM-Fc chimera and by an antibody interfering with ALCAM/ALCAM interactions. Altogether these data suggest that sALCAM is a marker of EOC, which correlates with more aggressive type II tumors, and that ADAM17/TACE activity and sALCAM itself mediate enhanced invasiveness.

No abstract

Serum concentrations of the CA 19-9 and CA 50 antigens were determined in 129 patients with malignant and benign biliary and pancreatic diseases. Values for the two markers were highly correlated (P < 0.001). The concentrations of CA 19-9 and CA 50 were positive in 84.6% and 80.7% of patients with pancreatic cancer, respectively. The overall specificity of CA 19-9 (92.4%) was slightly higher than that of CA 50 (88.5%). The sensitivity of CA 50 (91.3%) was greater than that of CA 19-9 (73.9%) in patients with diseases of the biliary tract. Elevated concentrations of CA 19-9 (12.9%) and CA 50 (35.2%) were also found in a number of cases with benign disease, especially in patients with obstructive jaundice. These data suggest that both CA 19-9 and CA 50 can be useful markers of pancreatic cancer in nonjaundiced patients. The joint use of the two markers does not yield a better diagnostic resolution than the use of either one alone.

The CD44 cell surface proteoglycan participates in a variety of CD44v6 has been also described in high-grade, but not in functions including lymphohematopoiesis, lymphocyte homing low-grade, non-Hodgkin's lymphomas. [25][26][27] and tumor metastasis. In addition to the standard form Upon interaction with its natural ligand, or when ligated by addition to these clinical and biological parameters, serum